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A trial fibrillation (AF) is a growing global epidemicassociated with significant morbidity and mortality.1,2
One of the most devastating complications associated with AF
is stroke, a highly preventable event through the appropriate
use of oral anticoagulation therapy. Furthermore, strokes
associated with AF have an increased likelihood of causing
death or disability.3 Although oral anticoagulation therapy can
significantly reduce the risk of AF-related stroke, numerous
international registries have demonstrated that guideline-
recommended prescription of anticoagulation remains sub-
optimal.4 A major advance in stroke prevention in recent
years has been the emergence of non-vitamin K oral
anticoagulants (NOACs) given their superior efficacy and
safety, predictable effect without routine monitoring, and
fewer interactions compared with warfarin. The availability of
NOACs is likely to be of great benefit in improving the rate of
appropriate anticoagulation use and thus stroke prevention.
However, despite increasing familiarity and comfort with their
general use, there are still specific clinical situations in which
more data are required to increase physician confidence in
their efficacy and safety.
It is in this context that in the current issue of the Journal of
the American Heart Association (JAHA) Dr Lee and colleagues
examine the use of anticoagulation for AF in a large cohort with
2 important characteristics: Asian ethnicity and comorbid
cirrhosis.5 Using the Taiwan National Health Insurance
Database, individuals with AF and cirrhosis were identified with
International Classification of Diseases, Ninth Revision and Tenth
Revision (ICD-9 and ICD-10) coding. An analysis was undertaken
to compare outcomes of cirrhotic individuals with AF treated
with NOACs (dabigatran, apixaban, or rivaroxaban) compared
with warfarin. A total of 1438 individuals were prescribed NOAC
therapy and 990 were prescribed warfarin. The major outcomes
examined in this study were ischemic stroke or systemic
embolism, intracranial hemorrhage, major gastrointestinal
bleeding, and major bleeding, as identified similarly by ICD
codes. Propensity score–based stabilized weights were utilized
to balance covariates in these analyses. Over a mean follow-up
period of just over 1 year, the authors report that treatment
with NOAC therapy was associated with a similar risk of
ischemic stroke or systemic embolism when compared with
warfarin (3.2% versus 3.7%, P=0.43). Furthermore, rates of
intracranial hemorrhage did not appear to differ between the 2
groups (1.0% versus 1.6%, P=0.10). Finally, a statistically lower
rate of major gastrointestinal bleeding (1.9% versus 3.6%,
P=0.003) and any major bleeding (2.9% versus 5.4%, P<0.001)
was observed in the NOAC group. While the widely used Child-
Pugh score was unable to be assessed in this study, outcomes
may also have differed in relation to type and severity of
cirrhosis. NOAC and warfarin therapy had no significant
difference in outcomes in the alcoholic cirrhotic group. In the
non-alcoholic cirrhotic group, however, NOAC therapy was
associated with less bleeding compared to warfarin. The
severity of cirrhosis was assessed by the presence of ICD-
coded complications such as ascites and hepatic encephalopa-
thy. Those with a lack of these complications, so-called
nonadvanced cirrhosis, had a reduction in major bleeding and
all bleeding risk with NOAC therapy. Advanced liver cirrhosis
was associated with a reduction in intracranial hemorrhage in
the NOAC group compared with warfarin.
This analysis by Dr Lee and colleagues is a welcome
addition to the growing body of real-world data supporting the
potential use of NOACs in patient subgroups underrepre-
sented in the major randomized clinical trials. In general, the
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subject of anticoagulation for AF in Asians is an important one
for a multitude of reasons. From a population perspective, the
burden of AF and its subsequent complications in Asia is of
great concern. While the prevalence of this condition is lower,
the absolute number of individuals living with AF in this region
significantly outnumbers those in North America and Europe
because of its populous nature.6 Moreover, this discrepancy is
expected to increase exponentially in coming decades as
Asian societies continue to expand and undergo demographic
transition.6 However, there are unique and important sub-
tleties that may alter the balance of efficacy and safety of
anticoagulation in Asian populations.7 First, Asians have a
higher baseline risk of bleeding and intracranial hemorrhage.7
Second, the rate of ischemic stroke appears be higher in
Asians.7 Third, the quality of warfarin anticoagulation seems
to be less in Asians, as assessed by time in therapeutic range;
this may be in part related to healthcare systems as well as
genetic influences.8 Finally, Asians more often have lower
body weight, reduced creatinine clearance, lesser use of
gastroprotectant drugs, and greater use of antiplatelet
medications – factors that are all relevant to anticoagulant
prescription.7 In spite of these factors, there is an increasing
wealth of recent information regarding the use of anticoag-
ulation in Asians with AF. Reassuringly, stroke and bleeding
risk can still be adequately assessed with the CHA2DS2-VASc
and HAS-BLED scores, respectively.7 From a practical point of
view, the available observational and randomized data also
support the general use of NOACs in preference to warfarin
anticoagulation in Asian patients with AF.9
On one hand, the present study provides further
evidence in support of NOAC use in Asian populations.
However, on the other hand, the issue of comorbid cirrhosis
confers another dimension on top of an already-existing
degree of uncertainty. As a result, no specific recommen-
dation is made in AF guidelines with regard to anticoagu-
lation in patients with cirrhosis, except for the inclusion of
liver disease as a component of the HAS-BLED bleeding
risk score.10,11 Yet, in addition to inducing a coagulopathy,
thrombosis may also be facilitated in cirrhosis by lower
levels of endogenous anticoagulants and higher levels of
procoagulants.12 Thus, patients with AF and cirrhosis are
likely to be at both increased thrombotic and bleeding risk.
Indeed, patients with cirrhosis appear to have a higher risk
of ischemic stroke.13 In the first instance, there is
observational evidence to suggest that warfarin anticoagu-
lation may be of benefit in AF patients with cirrhosis
compared with no anticoagulation. An analysis from the
same Taiwanese database has shown that warfarin use was
associated with a lower ischemic stroke rate but similar
intracranial hemorrhage rate compared with no antithrom-
botic or antiplatelet therapy in AF patients with cirrhosis.13
A subsequent meta-analysis has been undertaken in AF
patients with cirrhosis, of which notably 4 of the included 7
studies were in Asian populations; this provided further
support that warfarin users had a lower risk of stroke
compared with no anticoagulation (hazard ratio 0.58, 95%
CI 0.35–0.96), albeit at a cost of greater bleeding.14
However, there has been up until this point a paucity of data
on NOACs. All 4 major randomized controlled trials of NOACs
excluded patients with active liver disease. Only 2 studies were
included in the aforementioned observational meta-analysis
that compared NOACs and warfarin, in which warfarin was
found to have a higher bleeding risk (odds ratio 1.93, 95% CI
1.00–3.70).14 Other reports have only included a few patients
with AF and cirrhosis, suggesting similar or fewer bleeding risks
with NOACs compared with warfarin, but of insufficient sample
sizes to adequately compare thromboembolic outcomes.15–18
Given the lack of clinical data, pharmacokinetic properties have
provided reason to be cautious in the use of NOACs in liver
impairment.19 Body clearance, plasma protein binding, cyto-
chrome P450 metabolism, and biliary clearance can all be
affected in liver disease. Most NOACs have predominantly
hepatic clearance (apixaban 75%, rivaroxaban 65%, edoxaban
50%, and dabigatran 20%). Furthermore, free drug fractions can
increase when liver albumin synthesis is impaired because of
high plasma protein binding (rivaroxaban 95%, apixaban 85%,
edoxaban 55%, and dabigatran 35%). Moreover, cytochrome
P450 enzyme activity and biliary excretion is decreased in liver
impairment (apixaban and rivaroxaban are predominantly
metabolized by cytochrome P450; dabigatran and edoxaban
have minimal to none). Given these pharmacokinetic proper-
ties, cautious NOAC therapy has been thought until this time to
be reasonable in Child-Pugh A liver disease, not recommended
in Child-Pugh C liver disease, and variably recommended in
Child-Pugh B liver disease.19,20 The present study is thus an
important step forward in providing much useful observational
data regarding the safety of NOAC therapy in cirrhotic patients
given the absence of randomized evidence. In a much larger
sample size compared with prior clinical reports, the current
findings suggest that low-dose NOAC anticoagulation may be a
reasonable alternative to warfarin anticoagulation in Asian
patients with AF and cirrhosis in terms of thromboembolism,
and raise the possibility that they may even be superior from a
bleeding point of view.
A number of limitations to this analysis are worthwhile
mentioning, particularly as theymay represent opportunities for
future research. The findings of this data set cannot necessarily
be extrapolated to non-Asian populations for reasons discussed
above. In the absence of Child-Pugh scores, it is not known how
many patients had Child-Pugh B or C liver disease, although 19%
of patients onNOAC therapy had “advanced” liver disease in the
form of complications. It is also of paramount importance to
note that the vast majority of individuals in the NOAC group
(>90%) were taking low-dose NOAC therapy; thus, any
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conclusions regarding the safety of standard-dose therapy
cannot be drawn. Moreover, further studies should ideally
follow up patients for a longer period. Although the authors
state that only some of theNOACs had risk reductions thatwere
individually significant for bleeding end points, and other
subpopulations (eg, type and severity of cirrhosis) had NOAC
benefits on differing bleeding end points, the CIs were
overlapping and interaction tests that were presented were
nonsignificant, precluding conclusion on any true subgroup
differences. Several factors relevant to the risk of both
thromboembolic and bleeding complications were also not
able to be assessed in this data set. The time spent in the
therapeutic range for patients on warfarin was not available; it
may be possible that benefits fromNOACs are diminished with
higher time in therapeutic range on warfarin. Other factors
including blood pressure, renal function, and concomitant use
of other medications were also not reported; these may
increase bleeding risk and thus would be relevant to address-
ing this issue in the clinical setting. Study definitions were
dependent on coding data, which may be subject to inaccu-
racies or differ from those used elsewhere, preventing
between-study comparison. Finally, even though the present
data may represent the best available evidence on NOACs in
AF patients with cirrhosis, we cannot exclude the possibility of
residual confounding in the absence of randomization,
acknowledging that it is unlikely a large trial in this setting
will be undertaken in the near future.
In conclusion, this large, observational study makes a
significant contribution to the literature on the potential use of
NOAC therapy in Asians patients with AF and cirrhosis. Low-dose
NOAC therapy may be safe and efficacious in this setting in the
short term, despite the known differences in risk profiles and
outcomes in Asian populations with AF combined with the
balance of thrombosis and bleeding in cirrhosis. Some additional
areas of uncertainty remain unanswered, however, and we thus
look forward to future studies thatmay help us continue to reduce
the burden of AF and stroke in Asia and elsewhere.
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